Pharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) said on Tuesday that Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been granted Priority Review in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).
AstraZenecas supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) was based on results from a Phase III trial which showed Lynparza in combination with abiraterone reduced the risk of disease progression or death by 34% versus abiraterone alone. Median radiographic progression-free survival (rPFS) was 24.8 months for Lynparza plus abiraterone versus 16.6 for abiraterone alone.
Lynparza is being jointly developed and commercialised by AstraZeneca and Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada.
The two companies formed a global strategic oncology collaboration in July 2017 to co-develop and co-commercialise Lynparza and MEK inhibitor Koselugo (selumetinib) for multiple cancer types.
Lynparza is currently approved in the US for patients with homologous recombination repair (HRR) gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations) who have progressed following prior treatment with enzalutamide or abiraterone; and in the EU, Japan and China for patients with BRCA-mutated mCRPC who have progressed following prior therapy that included a new hormonal agent.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients